1. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study. Issue 4 (April 2019) Authors: Savona, Michael R; Odenike, Olatoyosi; Amrein, Philip C; Steensma, David P; DeZern, Amy E; Michaelis, Laura C; Faderl, Stefan; Harb, Wael; Kantarjian, Hagop; Lowder, James; Oganesian, Aram; Azab, Mohammad; Garcia-Manero, Guillermo Journal: Lancet Issue: Volume 6:Issue 4(2019) Page Start: e194 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Assessment of genotoxicity of pyrethrin in cultured human lymphocytes. (3rd July 2017) Authors: Azab, Mohammad; Khabour, Omar F.; Alzoubi, Karem H.; Hawamdeh, Hasan; Quttina, Maram; Nassar, Liliana Journal: Drug and chemical toxicology Issue: Volume 40:Number 3(2017:Jul.) Page Start: 251 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. Issue 2 (6th December 2017) Authors: Roboz, Gail J.; Kantarjian, Hagop M.; Yee, Karen W. L.; Kropf, Patricia L.; O'Connell, Casey L.; Griffiths, Elizabeth A.; Stock, Wendy; Daver, Naval G.; Jabbour, Elias; Ritchie, Ellen K.; Walsh, Katherine J.; Rizzieri, David; Lunin, Scott D.; Curio, Tania; Chung, Woonbok; Hao, Yong; Lowder, James... Journal: Cancer Issue: Volume 124:Issue 2(2018) Page Start: 325 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma. Issue 10 (2nd October 2016) Authors: Jueliger, Simone; Lyons, John; Cannito, Sara; Pata, Illar; Pata, Pille; Shkolnaya, Marianna; Lo Re, Oriana; Peyrou, Marion; Villarroya, Francesc; Pazienza, Valerio; Rappa, Francesca; Cappello, Francesco; Azab, Mohammad; Taverna, Pietro; Vinciguerra, Manlio Journal: Epigenetics Issue: Volume 11:Issue 10(2016) Page Start: 709 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. Issue 10 (October 2017) Authors: Kantarjian, Hagop M; Roboz, Gail J; Kropf, Patricia L; Yee, Karen W L; O'Connell, Casey L; Tibes, Raoul; Walsh, Katherine J; Podoltsev, Nikolai A; Griffiths, Elizabeth A; Jabbour, Elias; Garcia-Manero, Guillermo; Rizzieri, David; Stock, Wendy; Savona, Michael R; Rosenblat, Todd L; Berdeja, Jesus ... Journal: Lancet oncology Issue: Volume 18:Issue 10(2017:Oct.) Page Start: 1317 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Immunomodulatory activity of SGI-110: a basis for novel chemo-immunotherapeutic combinations in cancer treatment. (7th November 2013) Authors: Covre, Alessia; Parisi, Giulia; Nicolay, Hugues JMG; Fazio, Carolina; Fonsatti, Ester; Fratta, Elisabetta; Sigalotti, Luca; Taverna, Pietro; Choy, Gavin; Azab, Mohammad; Coral, Sandra; Maio, Michele Journal: Journal for immunotherapy of cancer Issue: Volume 1(2013)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Issue 9 (September 2015) Authors: Issa, Jean-Pierre J; Roboz, Gail; Rizzieri, David; Jabbour, Elias; Stock, Wendy; O'Connell, Casey; Yee, Karen; Tibes, Raoul; Griffiths, Elizabeth A; Walsh, Katherine; Daver, Naval; Chung, Woonbok; Naim, Sue; Taverna, Pietro; Oganesian, Aram; Hao, Yong; Lowder, James N; Azab, Mohammad; Kantarjian,... Journal: Lancet oncology Issue: Volume 16:Issue 9(2015:Sep.) Page Start: 1099 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Issue 9 (September 2015) Authors: Issa, Jean-Pierre J; Roboz, Gail; Rizzieri, David; Jabbour, Elias; Stock, Wendy; O'Connell, Casey; Yee, Karen; Tibes, Raoul; Griffiths, Elizabeth A; Walsh, Katherine; Daver, Naval; Chung, Woonbok; Naim, Sue; Taverna, Pietro; Oganesian, Aram; Hao, Yong; Lowder, James N; Azab, Mohammad; Kantarjian,... Journal: Lancet oncology Issue: Volume 16:Issue 9(2015:Sep.) Page Start: 1099 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Simultaneous Modeling of Biomarker and Toxicity Response Predicted Optimal Regimen of Guadecitabine (SGI‐110) in Myeloid Malignancies. (28th September 2017) Authors: Xu, Cong; Goggin, Timothy K.; Su, Xiang‐Yao; Taverna, Pietro; Oganesian, Aram; Lowder, James N.; Azab, Mohammad; Kantarjian, Hagop Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 6:Number 10(2017) Page Start: 712 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗